Integra LifeSciences Holdings Corporation. (NASDAQ:IART) Q4 2023 Earnings Conference Call February 28, 2024 8:30 AM ET

Company Participants

Christopher Ward - Senior Director of Investor Relations

Jan De Witte - President and Chief Executive Officer

Lea Knight - Chief Financial Officer

Conference Call Participants

Vik Chopra - Wells Fargo

Kristen Stewart - CL King

Ryan Zimmerman - BTIG

Jayson Bedford - Raymond James

Robert Marcus - JPMorgan

Steven Lichtman - Oppenheimer

Richard Newitter - Truist Securities

Craig Bijou - BofA Securities

David Turkaly - Citizens JMP

Joanne Wuensch - Citi

Operator

Good day, and thank you for standing by. Welcome to the Integra LifeSciences Fourth Quarter 2023 Financial Results. [Operator Instructions] Please be advised, today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Chris Ward, Senior Director of Investor Relations. Please go ahead.

Christopher Ward

Good morning, and thank you for joining the Integra LifeSciences Fourth Quarter 2023 Earnings Conference Call. Joining me on the call this morning are Jan De Witte, President and Chief Executive Officer; Lea Knight, Chief Financial Officer; Mathieu Aussermeier, Senior Vice President of Corporate Finance, Investor Relations and Treasurer.

This morning, we issued a press release announcing our fourth quarter 2023 financial results. The release and corresponding earnings presentation, which we will reference during the call, are available at integralife.com under Investors, Events and Presentations, in a file named Fourth Quarter 2023 Earnings Call Presentation.

Before we begin, I want to remind you that many of the statements made during this call may be considered forward-looking. Factors that could cause actual results to differ materially are discussed in the company's Exchange Act reports filed with the SEC and in the release.

Also in our prepared remarks, we will reference reporting an organic revenue growth and organic revenue growth, excluding Boston. For 2023 results, organic revenue growth excludes the effects of foreign currency, acquisitions, divestitures and discontinued products.

For 2024 guidance and reporting, organic revenue growth will no longer exclude discontinued products. Organic revenue growth, excluding Boston excludes the revenues from products manufactured in our Boston facility in both periods.

Management believes that excluding revenue from all products manufactured at the Boston plant provides useful information when evaluating the company's organic growth because of the unusual nature of the manufacturing stoppage and voluntary global recall. Unless otherwise stated, all disaggregated and franchise-level growth rates are based on organic performance.